Close

We use cookies to give you the best possible online experience. If you continue, we'll assume you are happy for your web browser to receive all cookies from our website. See our cookie policy for more information on cookies and how to manage them.

Aviva response to the Competition and Market Authority (CMA) investigation into the private healthcare market

Article date: 2 April 2014

The final report of the Competition Commission’s investigation into the private healthcare market puts in place several positive and welcomed changes that will help ensure better value for money for all private healthcare customers and self-pay patients across the UK.

The proposals will substantially increase competition in London, where some private hospitals have held market power with little effective competition, resulting in higher prices for customers. The investigation also found that competition between hospitals is weak in many local areas outside of London but the evidence of an impact on price was not strong enough to require divestments.

Together with improved transparency on the cost and performance of individual consultants and private hospitals, allowing customers to exercise choice, a much improved market will ensue, with customers able to access high quality care at more affordable prices

The removal of direct incentives to consultants and restrictions on equity ownership by them will also prevent referrals being influenced by a financial interest.

Mark Noble, managing director at Aviva UK Health, said: “We have been engaging with the Competition Commission throughout this thorough investigation and fully support their sensible and decisive remedies. In time, they will create a more sustainable and fairer market for all, and will engender better value for money for private healthcare customers.

“The removal of market power in London in particular will drive a much healthier, competitive approach to pricing, while all patients and GPs in the UK will be able to make more informed decisions on medical treatment through the publication of cost and performance data.

“The customer benefits of these remedies will take time to become manifest, but at Aviva we believe the market will significantly improve in the customers’ interest, ultimately allowing more people to access the important benefits of private healthcare.

“We will continue to work closely with hospitals and consultants, and any new ones, to ensure that the remedies of the CMA translate into high quality medical care for the best possible price for our customers.”

- Ends -

If you are a journalist and would like further information, please contact: Melissa Loughran: Aviva Press Office: 01904 452791: 07800 691947: Melissa.loughran@aviva.co.uk

Notes to editors:

  • Aviva provides 31 million customers with insurance, savings and investment products.
  • We are one of the UK’s leading insurers and one of Europe’s leading providers of life and general insurance.
  • We combine strong life insurance, general insurance and asset management businesses under one powerful brand.
  • We are committed to serving our customers well in order to build a stronger, sustainable business, which makes a positive contribution to society, and for which our people are proud to work.
  • The Aviva media centre at www.aviva.com/media/ includes images, company and product information and a news release archive
  • For an interactive introduction to what we do and how we do it, please click here http://www.aviva.com/library/reports/this-is-aviva/
  • For broadcast-standard video, please visit http://www.aviva.com/media/video/
  • Follow us on twitter: www.twitter.com/avivaplc/